Biotech in Autoimmune and Inflammatory Disease 2006, 2nd Edition - Biologics Market Research

Biotech in Autoimmune and Inflammatory Disease 2006, 2nd Edition

Published Date: May 2006
Published By: Arrowhead Publishers
Page Count: 263
Order Code: R608-13
Price: $2,999.00 Online Download
$7,499.00 Global Site License
$4,999.00 PDF Email From Publisher - Site License

DESCRIPTION
Despite their diversity, global healthcare systems are increasingly converging in the need and desire to contain costs of healthcare, and especially those associated with pharmaceuticals. At the same time, Big Pharma are having to contend with a dearth of invention, patent expirations, and increased generic competition, among other factors undermining their profits. In this environment, the importance of market access strategies, especially in terms of pricing, reimbursement and parallel trade are rapidly gaining prominence.
Pharmaceutical and Biotech Market Entrance Strategies examines the key issues that need to be addressed by pharmaceutical and biotechnology companies alike in order to successfully achieve return on investment. The American, European and Japanese markets are undergoing constant harmonisation changes, which are leading to a globalisation of operating procedures and state intervention in healthcare and drug cost containment. This trend has an important impact on the overall environment facing the drug and biotechnology industry - on the one hand, facilitating access to a wider patient base but, on the other, raising the stakes of key pricing and reimbursement decisions.
The value of biological drugs indicated for autoimmune diseases, which affect up to 5% of the total world population, was roughly $11 billion in 2005. Remicade, Enbrel, Humira and Avonex currently lead the autoimmune field. These drugs are transforming the treatment of autoimmune diseases. In addition, novel therapies for psoriasis, asthma, and lupus will in the near future add tremendous revenue to an already rapidly growing field.
Medical, pharmaceutical and biotechnological advances are increasingly supporting the use of biological drugs in the treatment of autoimmune and inflammatory diseases. Indeed, biologics are having a major impact on the treatment of those diseases for which there has been significant unmet need for decades. As the new drugs are capable of targeting disease-causing proteins in a more specific fashion, while also carrying lower risks of adverse side effects, they have considerable advantages over traditional treatments.
Given the above advantages, coupled with more commercial interest, better understanding of disease causes and higher levels of patient familiarity with the new medicines, biologics will continue to undermine the market share of traditional drugs.
This report assesses the current and future position of biologics in the fields of multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis and asthma.
Key Features of This Report:
Thorough financial breakdown of the leading products and companies making an impact in autoimmune disease therapy
Market analysis and differentiation of biotech vs. synthetic drugs in combatting autoimmune diseases
Financial forecasts for key autoimmune disease therapies as well as overall disease category value through 2010
Integrative discussion of clinical data and key trials for already marketed as well as emerging biologics
Identification and discussion of trends and issues that will have a significant impact on the future of biotech drug sales in the autoimmune market
Appraisal of development status for key biotech drugs being developed for various autoimmune diseases and discussion of research trends
Who Should Buy This Report:
Companies interested in understanding the wider opportunities and challenges in the autoimmune and inflammatory disease markets
Pharma/biotech companies wishing to identify opportunities and threats to products in these markets in order to examine a variety of profit maximization strategies
Companies interested in understanding the state of R&D in relation to multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis and asthma